Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
Status:
Completed
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK)
profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe
(PFS) as single subcutaneous (s.c.) injection of 40 mg.